Contact Us
TEL: +86-0571-88334626
Home > News > Content
Daptomycin Profile
Dec 26, 2018

Daptomycin is a new structure of cyclolipopeptide antibiotic extracted from Streptomyces fermentation broth. It was discovered by Eli Lilly and Company in the 1980s. It was developed by Cubist Pharmaceutical Company in 1997. It not only has novel chemistry. Structure, and its mode of action is also different from any approved antibiotic: it disrupts the amino acid transport of cell membranes, thereby hindering the biosynthesis of bacterial cell wall peptidoglycan, altering the properties of the plasma membrane, and can destroy in many ways. Bacterial cell membrane function and rapidly kill Gram-positive bacteria. In addition to acting on most clinically relevant Gram-positive bacteria, daptomycin is more potent in vitro against isolated strains that exhibit resistance to methicillin, vancomycin, and linezolid. This characteristic has very important clinical significance for critically ill patients.